Tang, Yujie
Gholamin, Sharareh
Schubert, Simone
Willardson, Minde I
Lee, Alex
Bandopadhayay, Pratiti
Bergthold, Guillame
Masoud, Sabran
Nguyen, Brian
Vue, Nujsaubnusi
Balansay, Brianna
Yu, Furong
Oh, Sekyung
Woo, Pamelyn
Chen, Spenser
Ponnuswami, Anitha
Monje, Michelle
Atwood, Scott X
Whitson, Ramon J
Mitra, Siddhartha
Cheshier, Samuel H
Qi, Jun
Beroukhim, Rameen
Tang, Jean Y
Wechsler-Reya, Rob
Oro, Anthony E http://orcid.org/0000-0002-6261-138X
Link, Brian A
Bradner, James E
Cho, Yoon-Jae
Article History
Received: 18 March 2014
Accepted: 29 May 2014
First Online: 29 June 2014
Competing interests
: The Dana-Farber Cancer Institute has licensed drug-like derivatives of JQ1 prepared in the Bradner laboratory to Tensha Therapeutics for clinical translation as cancer therapeutics. Dana-Farber and J.E.B. have been provided minority equity shares in Tensha. J.Q. has a consultant agreement with Tensha Therapeutics.